Sangamo Therapeutics (SGMO) Projected to Post Quarterly Earnings on Monday

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) is expected to post its Q4 2024 quarterly earnings results after the market closes on Monday, March 17th. Analysts expect Sangamo Therapeutics to post earnings of ($0.09) per share and revenue of $11.70 million for the quarter. Individual that are interested in registering for the company's earnings conference call can do so using this link.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last announced its quarterly earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.02). Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. The firm had revenue of $7.55 million during the quarter, compared to analyst estimates of $11.70 million. On average, analysts expect Sangamo Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Sangamo Therapeutics Stock Performance

Shares of NASDAQ:SGMO traded down $0.16 during trading hours on Tuesday, hitting $0.85. The stock had a trading volume of 11,672,149 shares, compared to its average volume of 7,633,831. The stock's fifty day simple moving average is $1.10 and its 200 day simple moving average is $1.41. Sangamo Therapeutics has a 1-year low of $0.30 and a 1-year high of $3.18. The firm has a market capitalization of $176.54 million, a price-to-earnings ratio of -1.13 and a beta of 1.49.

Remove Ads

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. Royal Bank of Canada reiterated a "sector perform" rating and set a $2.00 price objective on shares of Sangamo Therapeutics in a research note on Tuesday. StockNews.com lowered shares of Sangamo Therapeutics from a "buy" rating to a "hold" rating in a research note on Tuesday, December 24th. HC Wainwright reiterated a "buy" rating and set a $10.00 price objective on shares of Sangamo Therapeutics in a research note on Monday, January 27th. Wells Fargo & Company lowered their price objective on shares of Sangamo Therapeutics from $3.00 to $2.00 and set an "equal weight" rating on the stock in a research note on Tuesday, December 31st. Finally, Truist Financial lowered their price objective on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a "buy" rating on the stock in a research note on Thursday, January 23rd. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $5.17.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.